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Bacteriological diagnosis of 
childhood TB: a prospective 
observational study
Andrew J. Brent  1,2,3,4, Daisy Mugo1, Robert Musyimi1, Agnes Mutiso1, Susan Morpeth1, 
Michael Levin3 & J. Anthony G. Scott  1,2,5
Childhood TB diagnosis is challenging. Studies in adults suggest Microscopic Observation Drug 
Susceptibility (MODS) culture or the Xpert MTB/RIF assay might be used to expand bacteriological 
diagnosis. However data from children are more limited. We prospectively compared MODS and Xpert 
MTB/RIF with standard microscopy and culture using the BD MGIT 960 system among 1442 Kenyan 
children with suspected TB. 97 specimens from 54 children were TB culture-positive: 91 (94%) by MGIT 
and 74 (76%) by MODS (p = 0.002). 72 (74%) culture-positive and 7 culture-negative specimens were 
Xpert MTB/RIF positive. Xpert MTB/RIF specificity was 100% (99.7–100%) among 1164 specimens 
from 892 children in whom TB was excluded, strongly suggesting all Xpert MTB/RIF positives are true 
positives. The sensitivity of MGIT, MODS and Xpert MTB/RIF was 88%, 71% and 76%, respectively, 
among all 104 true positive (culture and/or Xpert MTB/RIF positive) specimens. MGIT, MODS and Xpert 
MTB/RIF on the initial specimen identified 40/51 (78%), 33/51 (65%) and 33/51 (65%) culture-confirmed 
pulmonary TB cases, respectively; Xpert MTB/RIF detected 5 additional culture-negative cases. The high 
sensitivity and very high specificity of the Xpert MTB/RIF assay supports its inclusion in the reference 
standard for bacteriological diagnosis of childhood TB in research and clinical practice.
Definitive diagnosis of tuberculosis (TB) rests on detection of M. tuberculosis from clinical specimens, but is 
difficult in children. While sputum smear microscopy underpins the WHO DOTS and Stop TB strategies for TB 
diagnosis in adults1, obtaining sputum is more difficult in children, and the yield of microscopy alone is very poor 
due to small numbers of bacilli in clinical specimens. Bacteriological diagnosis therefore depends on mycobac-
terial culture2.
Strengthening laboratory capacity is a key component of the Stop TB Strategy and Global Plan to Stop TB1,3. 
Commercial liquid culture methods like the BACTEC Mycobacteria Growth Indicator Tube (MGIT) system 
(BD Diagnostics, Sparks, MD, USA) offer higher sensitivity and more rapid results than traditional solid media. 
However, barriers to their uptake include cost, a lack of technically trained personnel, and the need for biosafety 
level 3 facilities3.
Microcolony culture techniques such as the Microscopic Observation Drug Susceptibility (MODS) assay have 
several potential advantages over conventional culture methods in low resource settings, including high sensi-
tivity; more rapid results that include drug susceptibility testing (DST); lower cost; and less stringent biosafety 
requirements making it applicable in biosafety level 2 facilities4. However only limited data exist on their use in 
children5–7, and no studies have compared MODS with MGIT for diagnosis of TB in young children; nor eval-
uated MODS yield from induced sputum samples, despite good evidence and international recommendations 
supporting sputum induction for childhood TB diagnosis2,8.
The Xpert MTB/RIF real-time PCR assay (Cepheid, Sunnyvale, CA, USA) offers a rapid and operationally 
simpler alternative to culture for detection of M. tuberculosis and rifampicin resistance9,10. A recent meta-analysis 
suggests modest sensitivity and high specificity for paediatric TB diagnosis11, and the latest WHO childhood TB 
guidelines (2014) recommend Xpert MTB/RIF as an alternative to conventional microscopy and culture - but 
acknowledge the “very low quality of evidence”2.
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We compared microscopy, MGIT and MODS culture, and the Xpert MTB/RIF assay for diagnosis of child-
hood TB in Kenya.
Participants. We prospectively assessed each diagnostic method among children presenting to Coast 
Provincial General Hospital and Kilifi County Hospital in Coast Province, Kenya. Between July 2010 and 
December 2011 children aged <15 years were investigated for TB if one or more of the following features of sus-
pected TB were present and they were not already on TB treatment: unexplained persistent cough for >2 weeks; 
pneumonia not responding to first line antibiotics; unexplained fever for >2 weeks; unexplained progressive 
weight loss or failure to thrive for >4 weeks; a history of close contact with a suspected or confirmed case of pul-
monary TB; or clinical suspicion of TB for any other reason.
Clinical procedures. Each child underwent a structured history and examination, chest radiography and 
tuberculin skin testing (TST) according to WHO guidelines2. Severe malnutrition was defined as weight for age 
z-score of <−3 or the presence of nutritional oedema12. Provider initiated testing and counseling for HIV was 
performed according to Kenyan national guidelines, which recommend testing for all inpatients, and for all 
patients investigated for TB, on an opt-out basis.
Children who were able to expectorate provided up to three spontaneous sputum samples. Sputum induction 
was performed on the remainder. If sputum induction was contraindicated (e.g. due to severe respiratory dis-
tress), gastric aspiration was performed. Sputum induction and gastric aspiration were performed according to 
international recommendations2. Further investigations including extra-pulmonary or repeat sputum sampling 
were performed at the discretion of the clinical team caring for the patient.
We classified children as Confirmed TB, Highly Probable TB, Possible TB or Not TB according to their clin-
ical, radiological and microbiological findings. Categories were defined a priori and based closely on published 
definitions (Fig. 1)13,14. Treatment protocols followed Kenyan national guidelines. Children treated for TB were 
followed up until completion of treatment at 6 months. Other children were also followed up for 6 months, or 
until TB could be confidently excluded. Final diagnostic assignments were revised in the light of follow up data.
Laboratory procedures. Specimens were transported to the laboratory at 2–8 °C and processed the same 
day. Sputum specimens were decontaminated using the modified Petroff ’s method and 4% sodium hydroxide15; 
centrifuged; and the sediment re-suspended in 2 ml culture broth containing Middlebrook 7H9 medium, oxalic 
acid, albumin, dextrose, and catalase (OADC, Becton Dickinson), and polymyxin, amphotericin B, nalidixic acid, 
trimethoprim, and azlocillin (PANTA, Becton Dickinson)16. After vigorous vortexing to ensure sample homog-
enization, two drops were used to make a smear for Ziehl Neelsen staining, and the remainder divided equally 
for MGIT, MODS, and Xpert MTB/RIF. Samples for Xpert MTB/RIF analysis were promptly frozen at −80 °C for 
analysis at the end of the study.
Liquid mycobacterial culture was performed using the MGIT 960 system and MODS assay. A laboratory 
technician (RM) first received one month MODS training at the Universidad Peruana Cayetano Heredia in Lima, 
Peru. Standard protocols were followed15,16, except that MODS plates were examined 3 times a week rather than 
daily for logistic reasons.
Positive cultures from both methods were identified as M. tuberculosis complex (MTBC) or non-MTBC by 
the BD MGIT TBc Identification test (BD Diagnostics, Sparks, MD, USA). They were then further speciated and 
probed for isoniazid and rifampicin resistance mutations by PCR, using the Hain Genotype® line probe assay 
platform (Hain Lifescience GmbH, Nehren, Germany). The Xpert MTB/RIF assay (version G4) was performed 
at the end of the study on specimens from all children treated for confirmed, highly probable or possible TB, and 
from children in whom TB had been excluded. Laboratory procedures were externally monitored through the UK 
NEQAS quality assurance scheme and annual Good Clinical Laboratory Practice audits (Qualogy, UK).
In order to compare the performance of MGIT and MODS, and to prevent observer bias in the interpretation 
of either result, laboratory technologists were blinded to the identity of the MODS portion of each specimen. 
Specimens were instead identified by an electronically generated random numeric code, the key to which was 
held by the Principal Investigator.
Statistical analysis. Data were analyzed at both the patient and the specimen level. We first performed 
a per patient analysis to compare the sensitivity of smear microscopy, MGIT, MODS and Xpert MTB/RIF for 
identification of culture confirmed pulmonary TB cases. We then included all specimens (pulmonary and 
extra-pulmonary) in a per specimen analysis to calculate the sensitivity of each method against the existing refer-
ence standard of a positive M. tuberculosis culture (by MGIT and/or MODS).
To explore the specificity of Xpert MTB/RIF we calculated the proportion of specimens from Not TB cases 
that were Xpert MTB/RIF positive. Having established the very high specificity of the Xpert MTB/RIF assay, we 
then repeated the per specimen analysis using a composite reference standard incorporating Xpert MTB/RIF, such 
that a specimen was considered positive if either culture or Xpert MTB/RIF identified M. tuberculosis.
We used McNemar’s χ2 test to compare proportions between tests on paired aliquots of the same sample. To 
investigate any learning effect as laboratory staff became more experienced with MODS we performed the χ2 test 
for trend in the proportion of M. tuberculosis culture positive specimens identified by MODS in each quarter, 
and the Wilcoxon rank sum test to compare MODS time to detection (TTD) in the first and second years of the 
study. We used the Wilcoxon signed rank test to compare TTD of MTBC by MODS and MGIT. Associations with 
a positive Xpert MTB/RIF assay were explored using univariable and multivariable logistic regression models 
adjusted for clustering at the patient level.
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Ethical approval and informed consent. The study was approved by the Kenya National Ethics 
Committee. All study procedures were performed in accordance with relevant guidelines and regulations. A 
parent or guardian provided written informed consent.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Figure 1. Childhood TB Case Definitions.
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Results
We identified 1500 children with features of suspected TB, 1442 of whom were investigated for TB (Fig. 2). Active 
TB was diagnosed in 212 (14.7%) children, including 54 (25.5%) with Culture-confirmed TB, 63 (29.7%) with 
Highly Probable TB, and 95 (44.8%) with Possible TB. Most cases (185, 87%) had pulmonary TB (PTB). Baseline 
demographic and clinical characteristics are summarized in Table 1. In keeping with previous studies, the propor-
tion of cases that were bacteriologically confirmed was higher among older children.
Per patient analysis of pulmonary TB cases. There were 51 cases of Culture-confirmed pulmonary TB. 
Smear microscopy, MGIT and MODS on the initial sputum specimen identified M. tuberculosis in 13 (25%), 40 
(78%) and 33 (65%) cases, respectively (Table 2). Sensitivity was highest for each method among smear positive 
samples; Xpert MTB/RIF identified 100% of smear-positive cases and 53% of smear-negative cases on the first 
sputum specimen (Table 2).
Second and third sputum specimens were obtained from 237 (16%) and 102 (7%) children, respectively. Eight 
(16%) culture confirmed PTB cases were culture negative from the initial sample but grew M. tuberculosis from a 
Figure 2. Patient enrolment and disease assignments.
Confirmed TB Highly Probable TB Treated for Possible TB Not TB (TB excluded) Not classifiable
(n = 54) (n = 63) (n = 95) (n = 892) (n = 338)
Patient demographics
Age
Median (IQR1), months 53 (21–112) 32 (13–61) 17 (10–68) 16 (9–40) 17 (9–48)
0 to 4 years 27 (50%) 47 (75%) 67 (70%) 750 (84%) 271 (80%)
5 to 9 years 14 (26%) 10 (16%) 15 (16%) 95 (11%) 45 (13%)
10 to 14 years 13 (24%) 6 (9%) 13 (14%) 47 (5%) 22 (7%)
Male sex 33 (61%) 32 (51%) 48 (51%) 469 (53%) 188 (56%)
Clinical features
Cough > 2 weeks 40 (74%) 37 (59%) 71 (75%) 425 (48%) 194 (57%)
Fever > 2 weeks 37 (69%) 24 (38%) 66 (69%) 375 (42%) 167 (49%)
Weight loss/FTT2 > 4 weeks 32 (59%) 29 (46%) 51 (54%) 385 (43%) 168 (50%)
Pneumonia not responding 
to first line antibiotics 22 (41%) 21 (33%) 35 (37%) 260 (29%) 144 (43%)
Close TB contact 24 (44%) 25 (40%) 23 (24%) 145 (16%) 62 (18%)
HIV infected 15 (28%) 15 (24%) 35 (37%) 121 (14%) 88 (26%)
Severely malnourished 19 (35%) 31 (49%) 40 (42%) 303 (34%) 119 (35%)
Pulmonary TB3 51 (94%) 57 (90%) 77 (81%) — —
Extra-pulmonary TB3 7 (13%) 6 (10%) 20 (21%) — —
Table 1. Baseline characteristics of children with and without TB. 1IQR, interquartile range. 2FTT, failure to 
thrive. 3Six patients with pulmonary TB also had extrapulmonary TB (4 with culture confirmed TB, 2 that were 
treated for possible TB).
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subsequent sputum sample. MGIT, MODS and Xpert MTB/RIF each demonstrated a modest incremental yield 
from additional specimens (Table 3). None of the 8 initial culture-negative specimens from confirmed PTB cases 
were Xpert MTB/RIF positive. However Xpert MTB/RIF did detect M. tuberculosis in sputum from 5 additional 
children with culture negative pulmonary TB (3 with clinically Highly Probable TB and 2 who were treated for 
Possible TB).
Per specimen analysis of pulmonary and extra-pulmonary specimens combined. A total of 2085 
specimens were obtained for mycobacterial culture. We were unable to do MODS on 182 samples due to holiday 
staffing shortages (169) or insufficient sample (13). A total of 1903 specimens were therefore included in the anal-
ysis, of which 1802 (95%) were sputum specimens, 33 (2%) were smear positive, and 97 (5%) were M. tuberculosis 
culture positive (Supplementary Appendix, Table S1). MGIT was more sensitive than MODS overall (93.8% vs 
76.3%, p = 0.002), among all sputum specimens, among induced sputum specimens, and among specimens from 
both younger and older children (Table 4).
There was weak evidence of an increase in MODS sensitivity (χ2 test for trend p = 0.038) and a decrease in 
TTD over time, with a median TTD of 16 (IQR 7 to 21) days in 2010 compared with 10 (7 to 14) days in 2011 
(p = 0.052; Supplementary Appendix, Fig. S1). Overall, TTD was slightly shorter for MODS than MGIT (11 [IQR 
6 to 15] days versus 12 [7 to 17] days, p = 0.001).
Discordant culture results were obtained for 29 specimens. Independent bacteriological confirmation of 
M. tuberculosis was available for 21/29 of these specimens, either by the Xpert MTB/RIF assay on the original 
specimen (15/29) and/or by isolation of M. tuberculosis from an independent specimen from the same patient 
(Supplementary Appendix, Table S2). The clinical picture strongly supported the presence of M. tuberculosis 
complex in the remaining 8 culture-discordant samples: 5 MGIT+/MODS− specimens came from children 
with clinically Highly Probable TB prior to culture results; 2 MGIT−/MODS+ specimens came from chil-
dren treated empirically for TB prior to the culture result although they did not meet the stringent definition 
AFB smear positive (N = 13) AFB smear negative (N = 38) Total (N = 51)
N Sensitivity (95% CI) N Sensitivity (95% CI) N Sensitivity (95% CI)
AFB smear microscopy 13 N/A N/A N/A 13 25.5 (14.3–39.6)
MGIT culture 13 100.0 (75.3–100.0) 27 71.1 (54.1–84.6) 40 78.4 (64.7–88.7)
MODS culture 13 100.0 (75.3–100.0) 20 52.6 (35.8–69.0) 33 64.7 (50.1–77.6)
MGIT + MODS culture 13 100.0 (75.3–100.0) 30 78.9 (62.7–90.4) 43 84.3 (71.4–93.0)
Xpert MTB/RIF 13 100.0 (75.3–100.0) 20 52.6 (35.8–69.0) 33 64.7 (50.1–77.6)
Table 2. Sensitivity of each method for detection of M. tuberculosis in the initial sputum specimen from 
patients with culture confirmed pulmonary TB.
Specimen N
Smear microscopy MGIT culture MODS culture
MODS + MGIT 
culture Xpert MTB/RIF
Test + (%)
Cum. 
yield* Test + (%)
Cum. 
yield* Test + (%)
Cum. 
yield* Test + (%)
Cum. 
yield* Test + (%)
Cum. 
yield*
1st specimen 51 13 (25%) 25% 40 (78%) 78% 33 (65%) 65% 43 (84%) 84% 33 (65%) 65%
2nd specimen 32 10 (31%) 33% 22 (69%) 82% 15 (68%) 73% 24 (75%) 90% 18 (56%) 69%
3rd specimen 23 7 (30%) 33% 14 (61%) 84% 13 (57%) 75% 15 (65%) 92% 13 (57%) 71%
Table 3. Cumulative sensitivity (incremental yield) of serial sputum specimens from patients with culture 
confirmed pulmonary TB. *Cum. yield = cumulative sensitivity of serial sputum specimens. In 4 (8%) cases of 
culture-confirmed pulmonary TB, culture confirmation was obtained from a subsequent specimen (n = 1) or 
from a specimen excluded from the analysis because MODS culture was not performed (n = 3).
MGIT positive MGIT negative
MGIT Sensitivity % 
(95% CI)
MODS Sensitivity % 
(95% CI) p value
MODS 
positive
MODS 
negative
MODS 
positive
MODS 
negative
Specimen type
All specimens 68 23 6 1807 93.8 (87.0–97.7) 76.3 (66.6–84.3) 0.002
All sputum specimens 61 22 6 1713 93.3 (85.9–97.5) 75.3 (65.0–83.8) 0.003
Induced sputum 40 18 6 1603 90.6 (80.7–96.5) 71.9 (59.2–82.4) 0.014
Age of patient
<5 years 28 14 5 1398 89.4 (76.9–96.5) 70.2 (55.1–82.7) 0.039
5–14 years 36 8 1 380 97.8 (88.2–99.9) 82.2 (67.9–92.0) 0.039
Table 4. Comparison of MGIT and MODS culture sensitivity against culture reference standard incorporating 
both MGIT and MODS.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 11808  | DOI:10.1038/s41598-017-11969-5
of Highly Probable TB; and one MGIT+/MODS− specimen that grew M. bovis BCG came from a 4 month 
old HIV-infected child who had a clinical syndrome consistent with disseminated BCG disease (Supplementary 
Appendix, Table S2). All were the only positive cultures in their batch, arguing against cross-contamination caus-
ing the discordance. Even if cross-contamination were the cause and these specimens considered culture negative, 
MGIT would remain more sensitive than MODS (95.5% vs 80.9%, p = 0.005).
Xpert MTB/RIF identified 72/97M. tuberculosis culture positive specimens, giving a sensitivity compared to 
culture of 74.2% (95% CI 64.3 to 82.6). Xpert MTB/RIF was also positive on 5/86 (6%) specimens from patients 
with culture-negative but clinically highly probable TB, and 2/179 (1%) specimens from children treated for 
possible TB. No other specimens were Xpert MTB/RIF positive, including none of 1164 specimens obtained from 
children in whom TB was subsequently excluded - giving a specificity of 100% (1 sided 97.5% CI 99.7 to 100%) 
and strongly suggesting positive Xpert MTB/RIF results should be interpreted as true positives.
Against the composite reference standard of a positive TB culture and/or Xpert MTB/RIF result, the sensi-
tivity of TB culture was 93.3% (86.6 to 97.3), compared with 76.0% (66.6 to 83.8) for Xpert MTB/RIF (p = 0.002; 
Table 5). The sensitivity of MGIT and MODS culture alone were 87.5% (79.6 to 93.2) and 71.2% (61.4 to 79.6), 
respectively.
Table 6 shows Xpert MTB/RIF sensitivity against the composite reference standard, broken down by smear 
status, specimen type, age and HIV status. Sensitivity was higher for smear positive specimens (100% compared 
with 65% for smear negative specimens, p < 0.001), with a trend towards higher sensitivity among sputum sam-
ples. Neither age nor HIV status were associated with Xpert MTB/RIF yield in univariable or multivariable 
analyses.
Xpert MTB/RIF identified rifampicin resistance in 4 specimens from the same child, all of which were con-
firmed resistant to rifampicin by MODS and the GenoType MTBDRplus assay. MODS did not identify any other 
rifampicin resistant isolates.
Discussion
The lack of reliable diagnostic tools is the single greatest obstacle to improved childhood TB case management, 
particularly in low resource settings where the disease burden is greatest. Expansion of TB laboratory diagnostic 
capacity provides an opportunity to improve both diagnosis and surveillance in many settings3. However good 
quality data on the performance of each method are required to optimize their use and interpretation.
Few studies have compared laboratory methods for childhood TB diagnosis. Limitations of existing studies 
include small numbers of confirmed TB cases5–7,14,17–22, particularly among young children in whom diagnosis is 
most challenging5–7,14,19,22, and exclusion of ‘gold standard’ methods for specimen collection and/or mycobacterial 
culture5–7,17,20,23–26. Strengths of this study include the use of both sputum induction and liquid mycobacterial 
culture in keeping with current international recommendations2, and rigorous diagnostic assignments based on 
detailed clinical assessment and follow up. Prospective recruitment of all children who met broad, pre-defined 
inclusion criteria also ensures generalizability to a wide range of settings and clinical syndromes, including among 
children under 5 years who accounted for 81% of those investigated and half of all confirmed cases.
While comparison of culture yield between studies is hampered by widely varying clinical definitions, speci-
men types and culture methods, the proportion of culture-confirmed cases in our study is consistent with other 
studies using liquid mycobacterial culture for paediatric diagnosis5,8,14,18,20,26–30.
In our study MGIT was more sensitive than MODS culture. This is in keeping with the only other published 
study comparing MGIT with MODS for paediatric TB diagnosis5. Importantly we were also able to demonstrate 
the higher yield of MGIT for culture of paediatric induced sputum samples. These results contrast with other 
studies in adults in which MODS compared more favourably with MGIT4. The paucibacillary nature of childhood 
TB may have a role, and variation between centres also suggests MODS performance is operator dependent4. In 
support of this, even after one month residential training with an experienced team, we were able to demonstrate 
a learning effect with increasing MODS yield and reducing time to detection during the two years of the study. We 
did not compare MODS with culture on solid media, however other studies have shown MODS to be superior to 
Lowenstein Jensen media for diagnosis of childhood TB6,7,26.
Against a reference standard of mycobacterial culture, Xpert MTB/RIF sensitivity was similar to other paedi-
atric studies11, and comparable to MODS - in keeping with the only other study to compare the two methods29. 
Culture positive Culture negative
Culture Sensitivity % 
(95% CI)
Xpert MTB/RIF 
Sensitivity % (95% CI) p value
Xpert 
positive
Xpert 
negative
Xpert 
positive
Xpert 
negative
Specimen type
All specimens 72 25 7 1452 93.3 (86.6–97.3) 76.0 (66.6–83.8) 0.002
All sputum specimens 68 21 7 1419 92.7 (85.6–97.0) 78.1 (68.5–85.9) 0.008
Induced sputum 47 17 5 1356 92.8 (83.9–97.6) 75.4 (63.5–84.9) 0.011
Age of patient
<5 years 32 15 7 1152 87.0 (75.1–94.6) 72.2 (58.4–83.5) 0.088
5–14 years 40 10 0 300 100 (92.9–100) 80.0 (66.3–90.0) 0.002
Table 5. Comparison of culture and Xpert MTB/RIF sensitivity against composite reference standard of both 
culture and Xpert MTB/RIF.
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Significantly, a combination of culture and Xpert MTB/RIF increased bacteriological yield without compromising 
specificity.
Importantly, we were able to confirm the very high specificity of Xpert MTB/RIF in a large sample of speci-
mens from children in whom TB had been excluded by careful clinical, radiological and laboratory assessment 
and follow up. Positive Xpert MTB/RIF results have been reported in a small number of child TB suspects who 
did well at follow up without TB treatment11,24. However the very high precision with which we were able to 
demonstrate 100% specificity of Xpert MTB/RIF in a carefully characterized group of children without TB sug-
gests that these apparent false positive results from TB suspects in very high burden settings may have represented 
self-limiting pulmonary tuberculosis. This is well recognized in the pre-chemotherapy literature31.
Our primary analysis compared Xpert MTB/RIF sensitivity with the current culture reference standard. 
Having demonstrated the very high specificity of Xpert MTB/RIF we then repeated the analysis using a compos-
ite reference standard of positive culture or Xpert MTB/RIF. Composite reference standards should be used with 
care32. However, given the equivalent high specificities of Xpert MTB/RIF and mycobacterial culture, incorpora-
tion bias in favour of Xpert MTB/RIF is unlikely. Furthermore, misclassification bias arising from the imperfect 
sensitivity of culture may bias estimates of the accuracy of Xpert MTB/RIF culture alone is used as the refer-
ence33,34. We believe the composite reference standard therefore provides a fairer comparison of the two methods, 
and a better estimate of the true sensitivity of the Xpert MTB/RIF assay.
One potential limitation of our study is that molecular typing was not performed on MGIT-MODS discordant 
culture isolates to exclude cross-contamination. Nevertheless there was strong microbiological and/or clinical 
evidence to corroborate the positive culture in every case. In addition, negative controls in every MGIT batch and 
MODS plate provided no evidence of cross-contamination throughout the study, consistent with the very low 
prevalence and concentrations of M. tuberculosis in these paediatric specimens.
Due to finite resources, most children only had a single sputum sample obtained. Although this and other 
studies show the incremental yield of additional specimens where obtained, analysis of a single specimen is likely 
to reflect practice in most low resource settings due to the incremental cost of processing additional specimens.
In conclusion, our results underline the imperfect sensitivity of all currently available methods for bacteriolog-
ical diagnosis of childhood TB. The choice of method in any particular setting depends on several factors includ-
ing prevalence of TB and drug resistance; resources available to risk stratify patients for testing; test sensitivity, 
cost35, time to detection; and the availability of trained staff and laboratory biosafety facilities. Our data confirm 
the superior sensitivity of MGIT compared with MODS and Xpert MTB/RIF. Although MODS may have a role 
in some settings, the operationally simpler Xpert MTB/RIF assay was as sensitive as MODS, demonstrated equiv-
alent specificity to MGIT, and combined with MGIT it optimized bacteriological yield. Together these results 
strengthen the evidence base for inclusion of Xpert MTB/RIF in the reference standard for bacteriologically 
confirmed childhood TB in both WHO clinical guidelines35 and research.
Role of the funding source. The study was supported by the Wellcome Trust in the form of research fel-
lowships to AJB (081697) and JAGS (098532), and a core grant to the KEMRI-Wellcome Trust research pro-
gramme (077092); and by a project grant from the Pneumonia Etiology Research for Child Health (PERCH) 
project funded by the Bill & Melinda Gates Foundation at Johns Hopkins Bloomberg School of Public Health. The 
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